NEUEXCELL
Live / Applied — Fifth extension granted (statement of use) (as of 24 Oct 2025)
What this means for you
Not registered yet, but its 22 Oct 2021 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97087345
- Mark type
- Stylized text
- Filed
- 22 Oct 2021
- Published for opposition
- 14 Feb 2023
- Attorney of record
- Lawrence M. Green
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for treating Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Huntington's Disease, epilepsy, spinal cord injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, viral and baterial infections, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, and cerebral venous sinus thrombosis
Owner
- NeuExcell Therapeutics Inc., Philadelphia, PA, US
- NeuExcell Therapeutics Inc., State College, PA, US
Prosecution history
- 24 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Oct 2025 — SOU EXTENSION 5 GRANTED
- 22 Aug 2025 — SOU EXTENSION 5 FILED
- 22 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Mar 2025 — SOU EXTENSION 4 GRANTED
- 23 Mar 2025 — SOU EXTENSION 4 FILED
- 23 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 28 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Aug 2024 — SOU EXTENSION 3 GRANTED
- 28 Aug 2024 — SOU EXTENSION 3 FILED
- 28 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 06 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Mar 2024 — SOU EXTENSION 2 GRANTED
- 05 Mar 2024 — SOU EXTENSION 2 FILED